<DOC>
	<DOC>NCT01782261</DOC>
	<brief_summary>Assessment of the effect of incretin based therapies (Liraglutide and Saxagliptin) on immune cells in healthy subjects and patients with type 1 diabetes</brief_summary>
	<brief_title>Incretin Effect on the Immunological Phenotype</brief_title>
	<detailed_description>Assessment of immunological effects of Saxagliptin and Liraglutide on immune cells of the peripheral blood.</detailed_description>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Incretins</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>healthy subjects or patients with type 1 diabetes pregnancy treatment with GLP1Analoga (Liraglutide, Exenatide) treatment with DPP4inhibitor (Sitagliptin, Vildagliptin, Saxagliptin) chronic disease including a longterm medication over 4 weeks per year (except type 1 diabetes)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>autoimmune disease</keyword>
	<keyword>diabetes type 1</keyword>
	<keyword>incretin effect</keyword>
</DOC>